top of page

Our Portfolio 

Our portfolio reflects the scale and diversity of the broader healthcare venture capital market.


For over 13 years, we have created customized solutions for venture funds, corporate venture funds, limited partnership interests, operating companies, and individual shareholders.


23andMe was founded in 2006 to help people access, understand and benefit from the human genome. 


QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. It was acquired by Shionogi Pharma Inc. in 2017.


Akebia is focused on the development of therapeutics based on hypoxia-inducible factor biology. IPO in 2014 (NASDAQ: AKBA).


Aerpio Pharmaceuticals focuses on  leveraging Tie2 activation for ocular disease and vascular stabilization. IPO in 2018 (NASDAQ: ARPO).


Esperion Therapeutics 

focuses on the development of bempedoic acid. IPO in 2013 (NASDAQ: ESPR).


AcelRx Pharmaceuticals  focuses on the development and commercialization of innovative therapies. IPO in 2011 (NASDAQ: ACRX).


Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology.


Inivata is a leader in liquid biopsy. Its InVision® platform unlocks key genomic information from a simple blood test to transforming patient cancer care.


Immunocore researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.

bottom of page